CEGE: CEO Discusses Takeda Agreement for GVAX Immunotherapy in Prostate Cancer
[?]
Submitted By Knobias ClipReport
Shares of Cell Genesys, Inc. (CEGE) surged in today’s session following the announcement of a global alliance with Takeda Pharmaceutical Company Limited for the development and commercialization of GVAX immunotherapy for prostate cancer.